{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:51:20Z","timestamp":1787014280753,"version":"build-2736575974"},"reference-count":42,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2024,7]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n To characterize the long\u2010term (56\u2010week) benefits of continuous onabotulinumtoxinA treatment response in individuals with chronic migraine (CM) who achieved reduction to <15\u2009headache days\/month with treatment.<\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n There are limited data exploring reductions in monthly headache days to levels consistent with episodic migraine among those experiencing CM. Understanding the impact of sustained preventive treatment response in CM can provide important information about the impact of successful therapy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The two Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy trials of onabotulinumtoxinA in adults included a 24\u2010week, randomized, double\u2010blind, placebo\u2010controlled phase and a 32\u2010week open\u2010label phase. Data were pooled to determine proportions of individuals with <15\u2009headache days\/month while on treatment during several time periods in the double\u2010blind phase (Weeks 21\u201324; any 12 consecutive weeks; Weeks 13\u201324) and the entire study (Weeks 53\u201356; any 12 consecutive weeks; any 4\u2010week period). We assessed the long\u2010term impact on mean monthly headache days and changes from baseline on the six\u2010item Headache Impact Test (HIT\u20106) and Migraine\u2010Specific Quality of Life questionnaire version 2.1 (MSQv2.1).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n We analyzed 1384 participants with chronic migraine (double\u2010blind: onabotulinumtoxinA,\n n<\/jats:italic>\n \u2009=\u2009688; placebo,\n n<\/jats:italic>\n \u2009=\u2009696; open\u2010label:\n n<\/jats:italic>\n \u2009=\u2009688 [onabotulinumtoxinA]). The discontinuation rates prior to the completion of the full 56\u2010week treatment period for onabotulinumtoxinA and placebo were 25.4% (\n n<\/jats:italic>\n \u2009=\u2009175) and 29.3% (\n n<\/jats:italic>\n \u2009=\u2009204), respectively. During Weeks 13\u201324 of the double\u2010blind phase, significantly more onabotulinumtoxinA\u2010treated (386\/688 [56.1%]) than placebo\u2010treated (342\/696 [49.1%]) individuals had <15\u2009headache days\/month (\n p<\/jats:italic>\n \u2009=\u20090.010), with fewer monthly headache days for onabotulinumtoxinA versus placebo responders. The proportions of participants achieving <15 monthly headache days with onabotulinumtoxinA were 60.9% (419\/688) at Weeks 25\u201356, 81.1% (558\/688) at Weeks 53\u201356, and 79.4% (546\/688) during any consecutive 12\u2010week period. Mean changes from baseline on the HIT\u20106 and MSQv2.1 questionnaire surpassed within\u2010group minimal important difference thresholds in all periods. At Week 24, onabotulinumtoxinA\u2010treated participants who achieved <15 monthly headache days during Weeks 21\u201324 had a greater mean HIT\u20106 score reduction (\u22126.5 vs. \u22121.4) and greater mean MSQv2.1 Role\u2010Function Restrictive score improvements (21.3 vs. 6.4) than those who did not achieve <15 monthly headache days during the same period.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Participants who achieved <15 monthly headache days with onabotulinumtoxinA treatment achieved meaningful benefits in headache\u2010related disability and migraine\u2010specific quality of life compared with those who remained at or above the 15\u2013monthly headache days threshold. Sustained benefits observed over 56\u2009weeks support long\u2010term onabotulinumtoxinA use for the prevention of CM.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/head.14743","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T03:53:33Z","timestamp":1719028413000},"page":"838-848","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials"],"prefix":"10.1111","volume":"64","author":[{"given":"Stephen D.","family":"Silberstein","sequence":"first","affiliation":[{"name":"Jefferson Headache Center Thomas Jefferson University Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Department of Neuroepidemiology Institute for Medical Informatics, Biometry and Epidemiology University of Duisburg\u2010Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-6790","authenticated-orcid":false,"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[{"name":"Department of Neurology Mayo Clinic Phoenix Arizona USA"},{"name":"Atria Academy of Science and Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sommer","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie Company Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-2897","authenticated-orcid":false,"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Department of Neurology, Montefiore Headache Center Albert Einstein College of Medicine Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS)","volume":"31","author":"Blumenfeld AM","year":"2011","journal-title":"Cephalalgia"},{"key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0333102411398400","article-title":"Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review","volume":"31","author":"Lanteri\u2010Minet M","year":"2011","journal-title":"Cephalalgia"},{"key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/head.12878","article-title":"A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: demographics and headache\u2010related disability","volume":"56","author":"Lipton RB","year":"2016","journal-title":"Headache"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","article-title":"Medication\u2010overuse headache: risk factors, pathophysiology and management","volume":"12","author":"Diener HC","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers","volume":"81","author":"Buse DC","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double\u2010blind, randomized, placebo\u2010controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora SK","year":"2010","journal-title":"Cephalalgia"},{"key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double\u2010blind, randomized, placebo\u2010controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener HC","year":"2010","journal-title":"Cephalalgia"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1468-2982.2000.00117.x","article-title":"Guidelines for controlled trials of drugs in migraine: second edition","volume":"20","author":"Tfelt\u2010Hansen P","year":"2000","journal-title":"Cephalalgia"},{"key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults","volume":"38","author":"Tassorelli C","year":"2018","journal-title":"Cephalalgia"},{"key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double\u2010blind, randomized, placebo\u2010controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick DW","year":"2010","journal-title":"Headache"},{"key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpain.2014.11.004","article-title":"Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example","volume":"16","author":"Dodick DW","year":"2015","journal-title":"J Pain"},{"key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40122-020-00199-9","article-title":"The impact of onabotulinumtoxinA vs. placebo on efficacy outcomes in headache day responder and nonresponder patients with chronic migraine","volume":"9","author":"Silberstein SD","year":"2020","journal-title":"Pain Ther"},{"key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40122-020-00198-w","article-title":"Benefits beyond headache days with onabotulinumtoxinA treatment: a pooled PREEMPT analysis","volume":"9","author":"Diener HC","year":"2020","journal-title":"Pain Ther"},{"key":"e_1_2_13_15_1","first-page":"9","article-title":"The international classification of headache disorders, 2nd ed","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","journal-title":"Cephalalgia"},{"key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six\u2010item short\u2010form survey for measuring headache impact: the HIT\u20106","volume":"12","author":"Kosinski M","year":"2003","journal-title":"Qual Life Res"},{"key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0333102410379890","article-title":"Validation of the headache impact test (HIT\u20106) across episodic and chronic migraine","volume":"31","author":"Yang M","year":"2011","journal-title":"Cephalalgia"},{"key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0333102416652092","article-title":"OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program","volume":"36","author":"Lipton RB","year":"2016","journal-title":"Cephalalgia"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/0333102413497599","article-title":"What is a clinically relevant change on the HIT\u20106 questionnaire? An estimation in a primary\u2010care population of migraine patients","volume":"34","author":"Smelt AF","year":"2014","journal-title":"Cephalalgia"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","article-title":"Development and validation of the migraine\u2010specific quality of life questionnaire","volume":"38","author":"Jhingran P","year":"1998","journal-title":"Headache"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s11136-007-9217-1","article-title":"Validation of the migraine\u2010specific quality of life questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment","volume":"16","author":"Cole JC","year":"2007","journal-title":"Qual Life Res"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1526-4610.2007.00950.x","article-title":"The impact of topiramate on health\u2010related quality of life indicators in chronic migraine","volume":"47","author":"Dodick DW","year":"2007","journal-title":"Headache"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1468-2982.2009.01852.x","article-title":"Minimal important differences in the migraine\u2010specific quality of life questionnaire (MSQ) version","volume":"29","author":"Cole JC","year":"2009","journal-title":"Cephalalgia"},{"key":"e_1_2_13_24_1","doi-asserted-by":"crossref","DOI":"10.1016\/S1098-3015(11)72629-8","article-title":"Modified last observation carried forward is a superior method of imputation [abstract PND48]","volume":"13","author":"DeGryse R","year":"2010","journal-title":"Value Health"},{"key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56\u2010week PREEMPT clinical program","volume":"51","author":"Aurora SK","year":"2011","journal-title":"Headache"},{"key":"e_1_2_13_26_1","first-page":"22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Hepp Z","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_13_27_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038972","article-title":"Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study","volume":"10","author":"Orlando V","year":"2020","journal-title":"BMJ Open"},{"key":"e_1_2_13_28_1","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long\u2010term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld AM","year":"2018","journal-title":"J Headache Pain"},{"key":"e_1_2_13_29_1","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-019-0976-1","article-title":"An open\u2010label prospective study of the real\u2010life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study","volume":"20","author":"Ahmed F","year":"2019","journal-title":"J Headache Pain"},{"key":"e_1_2_13_30_1","first-page":"477","article-title":"OnabotulinumtoxinA improves quality of life in chronic migraine: the PREDICT study","volume":"49","author":"Boudreau G","year":"2021","journal-title":"Can J Neurol Sci"},{"key":"e_1_2_13_31_1","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0921-8","article-title":"Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European headache federation","volume":"19","author":"Bendtsen L","year":"2018","journal-title":"J Headache Pain"},{"key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/head.13617","article-title":"Onabotulinumtoxin\u2010A in chronic migraine: should timing and definition of non\u2010responder status be revised? Suggestions from a real\u2010life Italian multicenter experience","volume":"59","author":"Vernieri F","year":"2019","journal-title":"Headache"},{"key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American headache society position statement on integrating new migraine treatments into clinical practice","volume":"59","author":"American Headache Society","year":"2019","journal-title":"Headache"},{"key":"e_1_2_13_34_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","journal-title":"Cephalalgia"},{"key":"e_1_2_13_35_1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1468-2982.2006.01172.x","article-title":"New appendix criteria open for a broader concept of chronic migraine","volume":"26","author":"Olesen J","year":"2006","journal-title":"Cephalalgia"},{"key":"e_1_2_13_36_1","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/head.14154","article-title":"Chronic versus episodic migraine: the 15\u2010day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency","volume":"61","author":"Ishii R","year":"2021","journal-title":"Headache"},{"key":"e_1_2_13_37_1","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/head.13966","article-title":"Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) study","volume":"60","author":"Buse DC","year":"2020","journal-title":"Headache"},{"key":"e_1_2_13_38_1","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-022-01408-w","article-title":"Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study","volume":"23","author":"Ornello R","year":"2022","journal-title":"J Headache Pain"},{"key":"e_1_2_13_39_1","first-page":"1344","article-title":"Effect of headache\u2010free days on disability, productivity, quality of life, and costs among individuals with migraine","volume":"26","author":"Lipton RB","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_13_40_1","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-023-01636-8","article-title":"Persistence to anti\u2010CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study","volume":"24","author":"Charleston L","year":"2023","journal-title":"J Headache Pain"},{"key":"e_1_2_13_41_1","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14740338.2021.1948531","article-title":"OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation","volume":"20","author":"Cheng F","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"e_1_2_13_42_1","first-page":"1119","article-title":"Real\u2010world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene\u2010related peptide monoclonal antibodies","volume":"29","author":"Schwedt TJ","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_13_43_1","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/head.13653","article-title":"FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine","volume":"59","author":"Rothrock JF","year":"2019","journal-title":"Headache"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:39:39Z","timestamp":1767613179000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/head.14743"],"URL":"https:\/\/doi.org\/10.1111\/head.14743","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"2023-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}